#United States #Chicago #cancer therapies #AVEO Oncology #Tivozanib

AVEO Oncology Showcases Key Research at ASCO 2025

AVEO Oncology, a subsidiary of LG Chem, made notable contributions to the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting held in Chicago, Illinois. The biopharmaceutical company presented three significant posters highlighting its commitment to innovation in cancer treatments, specifically focusing on its therapeutic pipeline aimed at improving the lives of cancer patients.

First Poster: Efficacy of Tivozanib

The first featured poster detailed the findings from an exploratory subgroup analysis of the TiNivo-2 study, which evaluated tivozanib as a second-line treatment option. This analysis focused on patients with metastatic renal cell carcinoma (mRCC) who had previously undergone treatment with immune checkpoint inhibitors and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). The study revealed that administering tivozanib monotherapy at a dosage of 1.34mg daily was effective, demonstrating substantial tumor size reductions in these patients. Notably, the results indicated that combining nivolumab with tivozanib did not yield any additional benefits, reinforcing the efficacy of tivozanib as a standalone treatment in this patient population.

Second Poster: FIERCE-HN Trial for Head and Neck Cancer

The second poster addressed the ongoing FIERCE-HN trial, a multi-center, randomized, double-blind, placebo-controlled phase 3 study. This trial investigates the combination of ficlatuzumab and cetuximab in patients suffering from recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). Key objectives include assessing both the efficacy and safety of the combination therapy compared to cetuximab alone. FIERCE-HN commenced enrollment in December 2023, with expectations to complete recruitment by May 2026, aiming for significant advancements in treatment options for this challenging cancer type.

Third Poster: AV-380 in Cancer Cachexia

Lastly, AVEO presented insights into the Phase 1b dose escalation study of AV-380, notably known by the generic name rilogrotug. This experimental study aims to evaluate the safety and effectiveness of this anti-GDF15 monoclonal antibody when combined with standard care for cancer patients experiencing cachexia. Rilogrotug represents a promising direction for addressing the debilitating effects of cachexia on cancer patients, which significantly impacts their quality of life. The trial highlighted the importance of targeting growth differentiation factor 15 (GDF-15) in improving patient outcomes in this area of high unmet medical need.

Conclusion

AVEO Oncology's participation at ASCO 2025 underscores its dedication to advancing cancer treatment through rigorous research and development. The presentations reflected the company's ongoing efforts to provide innovative oncology solutions that improve the lives of patients battling cancer. These groundbreaking findings not only contribute to the understanding of cancer therapies but also pave the way for future research in this critical field. As noted by Michael Bailey, AVEO's President and CEO, the company remains committed to pushing the envelope in oncology treatments, illustrating the potential of targeted therapies like tivozanib to redefine patient outcomes in cancer care.